ConductScience.org, home

Trial · NCT05225298

SARS-COV-2 Screening in Dialysis Facilities

NCT05225298, Not applicable, Completed, Stanford University; results first posted 2024-10-30

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. SARS-COV-2 Screening in Dialysis Facilities. Trials, record NCT05225298. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05225298

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
SARS-COV-2 Screening in Dialysis Facilities
NCT number
NCT05225298
Status
Completed
Phases
Not applicable
Enrollment
2,389 participants, actual
Lead sponsor
Stanford University
Conditions
End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease, Dialysis; Complications
Interventions
Offering SARS-CoV-2 test
First posted
2022-02-04
Last updated
2024-10-30
Results first posted
2024-10-30

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber and Percentage of Total SARS-CoV-2 Tests Accepted Out of Total Tests Offered3 months
SecondaryDeaths4 months
SecondaryHospitalizations4 months
SecondaryChange in Facility Scores on In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) Survey4 monthsthis survey is administered annually at each dialysis facility dialysis facility (based on Centers for Medicare Services regulation)

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYNumber and Percentage of Total SARS-CoV-2 Tests Accepted Out of Total Tests Offered3 monthsAll participants who started in the Participant FlowTestsCOUNT_OF_UNITS
SECONDARYDeaths4 monthsParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYHospitalizations4 monthsParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange in Facility Scores on In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) Survey4 monthsData were not collected for this outcome measure

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number and Percentage of Total SARS-CoV-2 Tests Accepted Out of Total Tests OfferedStatic Frequency509Tests
Number and Percentage of Total SARS-CoV-2 Tests Accepted Out of Total Tests OfferedDynamic Frequency475Tests
DeathsStatic Frequency31Participants
DeathsDynamic Frequency41Participants
HospitalizationsStatic Frequency310Participants
HospitalizationsDynamic Frequency444Participants

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDStatic Frequency1,06928
Overall StudySTARTEDDynamic Frequency1,32029
Overall StudyCOMPLETEDStatic Frequency1,06928
Overall StudyCOMPLETEDDynamic Frequency1,32029
Overall StudyNOT COMPLETEDStatic Frequency00
Overall StudyNOT COMPLETEDDynamic Frequency00

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityStatic Frequency311,069
Total, all-cause mortalityDynamic Frequency411,320
Total, other adverse eventsStatic Frequency00
Total, other adverse eventsDynamic Frequency00
Total, serious adverse eventsStatic Frequency00
Total, serious adverse eventsDynamic Frequency00

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
36976655DERIVEDPubMed
39298171DERIVEDPubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal years
U01AI169477SARS-COV-2 Screening in Dialysis Facilities: Building an Optimal Strategy to Protect High Risk PopulationsANAND, SHUCHI; CHERTOW, GLENN MATTHEW; PARSONNET, JULIESTANFORD UNIVERSITYNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES2022 to 2023

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource
Static Frequency vs Dynamic Frequency: HospitalizationsTrial comparisons
Static Frequency vs Dynamic Frequency: deaths from any causeTrial comparisons
Static Frequency vs Dynamic Frequency: DeathsTrial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05225298

GET https://conductscience.org/api/trials/v1/NCT05225298/registered